Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
Toclizumam Versus Dexamethasone in Severe Covid-19 Cases
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- South Valley University
- Target Recruit Count
- 69
- Registration Number
- NCT04519385
- Locations
- 🇪🇬
Qena faculty medicine, Qinā, Egypt
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- UNICEF
- Target Recruit Count
- 600
- Registration Number
- NCT04492501
- Locations
- 🇵🇰
Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 75
- Registration Number
- NCT04479358
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 453
- Registration Number
- NCT04476979
- Locations
- 🇬🇫
CH Andrée Rosemon, Cayenne, French Guiana
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 495
- Registration Number
- NCT04445272
- Locations
- 🇪🇸
Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain
🇪🇸Hospital Universitario Marqués Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Clínic i Provincial Barcelona, Barcelona, Spain
Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Queen's Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT04412772
- Locations
- 🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT04409262
- Locations
- 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇺🇸Baylor Scott & White Medical Center - Irving, Irving, Texas, United States
🇧🇷Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT04408638
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Terapii Komórkowych i Chorób Wewn?trznych, Wroc?aw, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Community Cancer Institute (CCI), Fresno, California, United States
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Beneficência Portuguesa de São Paulo
- Target Recruit Count
- 129
- Registration Number
- NCT04403685
- Locations
- 🇧🇷
HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil
🇧🇷Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil
🇧🇷UNIFESP, São Paulo, Sao Paulo, Brazil
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT04395222
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.